Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells

被引:41
|
作者
Le, WD [1 ]
Rowe, DB [1 ]
Jankovic, J [1 ]
Xie, WJ [1 ]
Appel, SH [1 ]
机构
[1] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
关键词
D O I
10.1001/archneur.56.2.194
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The pathogenesis of substantia nigra pars compacta neuronal injury in Parkinson disease (PD) remains unknown. Cerebrospinal fluid (CSF) has been reported to contain factors toxic to dopaminergic neurons. Objectives: To determine whether the cytotoxic effects of CSF of PD patients are specific for dopaminergic neurons, dependent on prior levodopa therapy, and mediated by the cytokine tumor necrosis factor alpha (TNF-alpha). Design: Specimens of CSF were evaluated in dopaminergic (MES 23.5) and nondopaminergic (N18TG2) cell lines for cytotoxicity by viability assay and by the inhibition of tyrosine hydroxylase. After specificity and time and dose response were established, CSF specimens were assayed in a blinded manner. The TNF-alpha levels in CSF were deter mined by enzyme-linked immunosorbent assay. The toxicity of TNF-alpha in MU 23.5 cells was determined. Setting: A university-based research facility. Subjects: There were 4 groups of subjects: normal control subjects (n = 10), control subjects with neurologic disease (n = 8), PD patients treated with levodopa (n = 10), and untreated subjects with PD (n = 20). Results: Specimens of CSF from 15 (50%) of 30 PD patients and 2 (11%) of 18 control subjects were cytotoxic to dopaminergic MES 23.5 cells and were nontoxic to the parental cell line N18TG2. There was no correlation between the degree of PD CSF cytotoxicity, levodopa therapy, or the severity and duration of PD. Terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate nick-end labeling (TUNEL) for DNA fragmentation suggested the involvement of apoptotic mechanisms. The inhibition of tyrosine hydroxylase was an early effect of cell injury by PD CSF and correlated with the viability assay. The mean TNF-alpha level was 2.6-fold higher in CSF specimens from PD patients than in those of controls. The addition of recombinant human TNF-alpha equivalent to the highest level determined in PD CSF was not cytotoxic to MES 23.5 cultures. Conclusions: Blinded CSF specimens from PD patients, regardless of therapy, contain factors that cause specific dopaminergic neuronal cell injury. These factors are present in a substantial proportion of CSF specimens from patients with early PD, before the institution of medical therapy. Levels of TNF-alpha are elevated in the CSF of PD patients, but TNF-alpha is not responsible for the cytotoxicity.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 50 条
  • [41] Cerebrospinal fluid biomarkers and cognitive impairment in patients with early Parkinson's disease
    Stav, A. L.
    Arsland, D.
    Hessen, E.
    Fladby, T.
    MOVEMENT DISORDERS, 2014, 29 : S365 - S366
  • [42] Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease
    Abe, T
    Isobe, C
    Murata, T
    Sato, C
    Tohgi, H
    NEUROSCIENCE LETTERS, 2003, 336 (02) : 105 - 108
  • [43] CARBAMAZEPINE DOPAMINERGIC EFFECTS - PRELIMINARY-STUDY WITH PARKINSON DISEASE PATIENTS
    BARROS, HMT
    LEITE, JR
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA LATINOAMERICANA, 1987, 37 (01): : 66 - 66
  • [44] Altered Cerebrospinal Fluid Levels of α-Synuclein and Aβ in Parkinson Disease
    Kotzbauer, Paul T.
    Buddhala, Chandana
    Campbell, Meghan C.
    Perlmutter, Joel S.
    ANNALS OF NEUROLOGY, 2013, 74 : S42 - S42
  • [45] Cerebrospinal Fluid Biomarkers for Parkinson Disease Diagnosis and Progression
    Shi, Min
    Bradner, Joshua
    Hancock, Aneeka M.
    Chung, Kathryn A.
    Quinn, Joseph F.
    Peskind, Elaine R.
    Galasko, Douglas
    Jankovic, Joseph
    Zabetian, Cyrus P.
    Kim, Hojoong M.
    Leverenz, James B.
    Montine, Thomas J.
    Ginghina, Carmen
    Kang, Un Jung
    Cain, Kevin C.
    Wang, Yu
    Aasly, Jan
    Goldstein, David
    Zhang, Jing
    ANNALS OF NEUROLOGY, 2011, 69 (03) : 570 - 580
  • [46] Cerebrospinal fluid markers of neurodegeneration in Parkinson's disease
    Vranova, H.
    Nevrly, M.
    Mares, J.
    Kanovsky, P.
    Stejskal, D.
    MOVEMENT DISORDERS, 2009, 24 : S285 - S286
  • [47] Metabolomic investigations in cerebrospinal fluid of Parkinson's disease
    Willkommen, Desiree
    Lucio, Marianna
    Moritz, Franco
    Forcisi, Sara
    Kanawati, Basem
    Smirnov, Kirill S.
    Schroeter, Michael
    Sigaroudi, Ali
    Schmitt-Kopplin, Philippe
    Michalke, Bernhard
    PLOS ONE, 2018, 13 (12):
  • [48] Cerebrospinal fluid biomarker for Parkinson's disease: An overview
    Maass, Fabian
    Schulz, Isabel
    Lingor, Paul
    Mollenhauer, Brit
    Baehr, Mathias
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2019, 97 : 60 - 66
  • [49] Cerebrospinal fluid protein biomarkers in Parkinson's disease
    Faizan, Mohd
    Sachan, Nidhi
    Verma, Oyashvi
    Sarkar, Alika
    Rawat, Neeraj
    Singh, Mahendra Pratap
    CLINICA CHIMICA ACTA, 2024, 556
  • [50] Cerebrospinal fluid orexin and sleep attacks in Parkinson disease
    Asai, Hirohide
    Hirano, Makito
    Furiya, Yoshiko
    Kanbayashi, Takashi
    Ikeda, Masanori
    Kiriyama, Takao
    Ueno, Satoshi
    ANNALS OF NEUROLOGY, 2008, 64 : S50 - S51